Hyperthermia, a cancer treatment using controlled heat to kill tumor cells, shows promise but faces limitations due to some ...

Sustained remission at 10 years was more common as well among the patients starting anti-TNFs right away, Toyoda told ...

This induction therapy therefore allows tumor remnants to be resected some 3 months after ILP thus avoiding limb amputation. TNF-α-based ILP is a well-established treatment that aims to avoid ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy ... TL1A or tumour necrosis factor-like ligand ...

In England, the maturing of the Systemic Anti-Cancer Therapy (SACT) dataset could help provide some answers. The commitment to SACT began in 2011, followed by phased implementation across the ...

2001). Patients with ICH had high levels of excitatory and inflammatory molecules such as glutamate, interleukin-6, and tumor necrosis alpha. These findings suggested that inflammation and ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...